Fingerprint
Dive into the research topics of 'Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically